Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

El estudio SMART ART

21 de septiembre de 2026 actualizado por: Ruanne Barnabas, MBChB, MSc, DPhil., Massachusetts General Hospital

Un ensayo aleatorizado secuencial de asignación múltiple de intervenciones escalables para la administración de ART en Sudáfrica: el estudio SMART ART

The investigators propose A Sequential Multiple Assignment Randomized Trial of scalable interventions for ART delivery in South Africa- the SMART ART study-a randomized study to test adaptive ART delivery for persons with detectable viral load and/or not engaged in care.The types of differentiated service delivery (DSD) that will be examined in this study are incentives, community-based ART, and home delivery. The study plans to enroll up to 900 participants-people living with HIV and who are eligible for ART and living in KwaZulu-Natal, South Africa. The study aims to maximize the proportion of ART eligible persons living with HIV who achieve viral suppression at 18 months. The study will also evaluate the preferences of clients and providers for differentiated service delivery, and evaluate the cost effectiveness of adaptive HIV treatment for those who are not engaged in care.

Descripción general del estudio

Descripción detallada

Of the 8 million people in South Africa living with HIV, only 56% are on antiretroviral therapy (ART), and 45% are virally suppressed, substantially below the UNAIDS goal of 73%. Detectable viral load results in HIV-associated morbidity and mortality, and HIV transmission. Patient barriers to care, such as missed wages, transport costs, and long wait times for clinic visits and ART refills, are associated with detectable viral load. HIV differentiated service delivery (DSD) has simplified ART delivery: incentives, multi-month scripts, fast-track ART, and community or home ART delivery motivate clients, reduce the frequency of clinic visits, and decongest clinics. DSD is standard for clients who achieve viral suppression and engage in care; however, DSD needs adaptation to serve clients who are not succeeding. Indeed, persons who are not engaged in care arguably need simplified, client-centered approaches even more than those who can successfully engage.

A suite of adaptive DSD strategies, including incentives strategies, community-based ART, and home delivery, have been tested among stable clients with viral suppression. Lottery incentives effectively change short-term behavior, increasing ART initiation.Community-based and home ART delivery increase ART coverage and simplify ART access overcoming clinic barriers11. For stable clients, these DSD activities are as effective as clinic-based care in terms of achieving and maintaining viral suppression, although among stable clients they have not shown superiority in viral suppression or cost savings. In contrast, DSD has the potential to improve rates of viral suppression and retention in care and save costs among persons not engaged in care. There is great potential that DSD systems can be client-responsive and system-efficient for subgroups requiring additional services, matching services with client needs. A sequential, comprehensive package of DSD approaches, with each step increasing the intensity of service provision - adaptive DSD - has not been tested to determine the proportion and characteristics of persons who would achieve viral suppression and retention in care and to estimate the cost-effectiveness and budget impact.

To increase population level viral suppression, persons with detectable viral load need responsive DSD interventions. A Sequential Multiple Assignment Randomized Trial (SMART) design facilitates evaluation of a stepped, adaptive approach to achieving viral suppression with 'right-sized' interventions. The investigators are an experienced team and propose to build on the strong partnerships to sequentially test adaptive DSD strategies for persons with detectable viral load and/or not engaged in care: incentives, community-based ART, and home delivery. As the Center for Community Based Research, the investigators maintain strong connections with stakeholders including department of health, traditional leaders and ward counsellors throughout the Greater Edendale Area (GEA) and the Vulindlela sub-district of the uMgungundlovu District Municipality. Due to the size of the recruitment target, this work will centre around the Caluza clinic but will extend into other parts of GEA and sub-district of Vulindlela over the course of recruitment. The aim is to identify the most effective and efficient HIV care delivery strategies.

Tipo de estudio

Intervencionista

Inscripción (Actual)

874

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • KwaZulu-Natal
      • Sweetwaters, KwaZulu-Natal, Sudáfrica
        • Human Sciences Research Council Sweetwaters

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Must be 18 years or older
  • Able and willing to provide informed consent for study procedures
  • Must self report that they will reside in the study community for the duration of follow-up
  • Living with HIV and eligible for ART by national guidelines, have a detectable viral load greater than the lower limit of detection and/or not engaged in care, and are stable clinically (CD4>100 cells, no moderate/severe screening laboratory abnormalities for kidney function i.e. eGFR >50 mL/min/1.73m2, not receiving treatment for active tuberculosis or other opportunistic infections).

Exclusion Criteria:

  • There are no separate exclusion criteria.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Investigación de servicios de salud
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Sin intervención: Best clinic practices

Participants start with best clinic practices and continue for 18 months (including participants who are non-responders at month 6 and are randomized to stay in their original arm)

Experimental: Best clinic practices plus lottery incentives

Participants start with best clinic practices plus lottery incentives and continue for 18 months (including participants who are non-responders at month 6 and are randomized to stay in the original arm)

Conditional lottery incentives Welcome back service (friendly providers, SMS, adherence support) Fast-track ART

Experimental: Randomized from best clinic practices to smart lockers

Second randomization into community ART through the use of smart lockers

Decentralized ART refills and monitoring, adherence support

Continue with best clinic practices

Experimental: Randomized from best clinic practices to home delivery

Second randomization into home ART delivery

Continue with best clinic practices

Home ART refill and monitoring, adherence support

Experimental: Randomized from best clinic practices plus lottery incentives to smart lockers

Second randomization into community ART through the use of smart lockers

Conditional lottery incentives Welcome back service (friendly providers, SMS, adherence support) Fast-track ART

Decentralized ART refills and monitoring, adherence support

Experimental: Randomized from best clinic practices plus lottery incentives to home delivery

Second randomization into home ART delivery

Conditional lottery incentives Welcome back service (friendly providers, SMS, adherence support) Fast-track ART

Home ART refill and monitoring, adherence support

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Viral suppression at 18 months
Periodo de tiempo: 18 months

The primary outcome is viral suppression at 18 months among the combined group of persons living with HIV who have detectable viral load and persons not engaged in care at enrollment.

18 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Retention in Care
Periodo de tiempo: 12 months

The proportion of clinical visits and medication refills missed over the last 12 months of the intervention

12 months
Time to ART initiation
Periodo de tiempo: 6 months

Time to antiretroviral therapy initiation

6 months
Engagement in care
Periodo de tiempo: 18 months

Proportion of people who are virally suppressed in each intervention arm

18 months
Comparison to viral suppression and retention outcomes from similar local clinics
Periodo de tiempo: 18 months

Proportion of individuals who are virally suppressed who are engaged in care in intervention arms compared to local clinics

18 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Ruanne V Barnabas, DPhil, University of Washington

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

2 de noviembre de 2021

Finalización primaria (Actual)

3 de julio de 2025

Finalización del estudio (Actual)

3 de julio de 2025

Fechas de registro del estudio

Enviado por primera vez

16 de septiembre de 2021

Primero enviado que cumplió con los criterios de control de calidad

11 de octubre de 2021

Publicado por primera vez (Actual)

22 de octubre de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

24 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

21 de septiembre de 2026

Última verificación

1 de enero de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 2022P001129
  • R01MH124465 (Subvención/contrato del NIH de EE. UU.)

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir